{"protocolSection":{"identificationModule":{"nctId":"NCT01575054","orgStudyIdInfo":{"id":"191622-116"},"secondaryIdInfos":[{"id":"2011-004980-63","type":"EUDRACT_NUMBER"}],"organization":{"fullName":"Allergan","class":"INDUSTRY"},"briefTitle":"BOTOX® Treatment in Adult Patients With Post-Stroke Lower Limb Spasticity"},"statusModule":{"statusVerifiedDate":"2016-08","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2012-05"},"primaryCompletionDateStruct":{"date":"2014-09","type":"ACTUAL"},"completionDateStruct":{"date":"2015-07","type":"ACTUAL"},"studyFirstSubmitDate":"2012-04-09","studyFirstSubmitQcDate":"2012-04-09","studyFirstPostDateStruct":{"date":"2012-04-11","type":"ESTIMATED"},"resultsFirstSubmitDate":"2015-10-01","resultsFirstSubmitQcDate":"2015-12-29","resultsFirstPostDateStruct":{"date":"2016-02-01","type":"ESTIMATED"},"lastUpdateSubmitDate":"2016-08-22","lastUpdatePostDateStruct":{"date":"2016-09-28","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Allergan","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"This study will evaluate the safety and efficacy of BOTOX® in the treatment of adult post-stroke lower limb spasticity."},"conditionsModule":{"conditions":["Muscle Spasticity"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":468,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"botulinum toxin Type A","type":"EXPERIMENTAL","description":"Double-Blind Study Phase (12 weeks): On Day 1, botulinum toxin Type A 300 U will be given by intramuscular injections into specified muscles of the lower limb, and an optional dose of 100 U may be injected into additional lower limb muscles. Open Label Study Phase: Up to 3 treatments with botulinum toxin Type A up to 400 U will be given by intramuscular injections to the lower limb approximately every 12 weeks over a 42 week period.","interventionNames":["Biological: botulinum toxin Type A"]},{"label":"Normal Saline (Placebo) Followed by botulinum toxin Type A","type":"OTHER","description":"Double-Blind Study Phase (12 weeks): On Day 1, normal saline (placebo) will be given by intramuscular injections into specified muscles of the lower limb, and optional injections may be administered into additional lower limb muscles. Open Label Study Phase: Up to 3 treatments with botulinum toxin Type A up to 400 U will be given by intramuscular injections to the lower limb approximately every 12 weeks over a 42 week period.","interventionNames":["Biological: botulinum toxin Type A","Drug: Normal Saline"]}],"interventions":[{"type":"BIOLOGICAL","name":"botulinum toxin Type A","description":"Double-Blind Study Phase (12 weeks): On Day 1, botulinum toxin Type A 300 U will be given by intramuscular injections into specified muscles of the lower limb, and an optional dose of 100 U may be injected into additional lower limb muscles. Open Label Study Phase: Up to 3 treatments with botulinum toxin Type A up to 400 U will be given by intramuscular injections to the lower limb approximately every 12 weeks over a 42 week period.","armGroupLabels":["Normal Saline (Placebo) Followed by botulinum toxin Type A","botulinum toxin Type A"],"otherNames":["BOTOX®","onabotulinumtoxin A"]},{"type":"DRUG","name":"Normal Saline","description":"Double-Blind Study Phase (12 weeks): On Day 1, normal saline (placebo) will be given by intramuscular injections into specified muscles of the lower limb, and optional injections may be administered into additional lower limb muscles.","armGroupLabels":["Normal Saline (Placebo) Followed by botulinum toxin Type A"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Change From Baseline in Modified Ashworth Scale-Bohannon (MAS-B) Score of Ankle Plantar Flexors Using a 6-Point Scale","description":"The MAS-B is a 6-point scale used to evaluate spasticity based on grading the resistance encountered in the ankle flexors by passively moving the ankle plantar flexor muscles through their range of motion. The score ranges from 0 (no increase in muscle tone) to 4 (affected part(s) rigid in flexion or extension). Scores are converted to a 0 to 5 grade. The average of the weeks 4 and 6 MAS-B ankle change from baseline is the primary end point. A negative number change from baseline indicates an improvement and a positive number change from baseline indicates a worsening.","timeFrame":"Baseline, 6 Weeks"}],"secondaryOutcomes":[{"measure":"Clinical Global Impression (CGI) of Overall Change by Physician Using a 9-Point Scale","description":"The CGI is a 9-point scale evaluating change from baseline status by the Physician. Scores range from +4 (very marked improvement) to -4 (very marked worsening). The average of the weeks 4 and 6 CGI by Physician score is used as a secondary end point. Higher scores indicate a greater improvement from baseline.","timeFrame":"Baseline, 6 weeks"},{"measure":"Goal Attainment Scores on the 6-Point Physician-Assessed Goal Attainment Scale (GAS)","description":"The physician-assessed GAS is an individualized, goal-oriented 6-point scale used to track functional improvement toward active and passive goals. GAS scoring ranged from -3 to 2 (-3 = worse than start; 0 = expected goal/attained the defined therapeutic goal; 2 = much more than expected/improvements clearly exceeded the defined therapeutic goal). Active and Passive Goal scores are presented.","timeFrame":"Week 8"},{"measure":"Change From Baseline in Average Pain Score While Walking on the 11-Point Pain Scale","description":"The patient is asked to select a number that best describes his/her pain while walking on an 11-point scale from 0 = \"no pain\" to 10 = \"pain as bad as can be imagined\". Patients are instructed to recall their average pain in the study limb during the 48-hour period prior to the visit. Patients with a baseline pain score \\>0 are included in the analyses.","timeFrame":"Baseline, Week 6"},{"measure":"Change From Baseline in Modified Ashworth Scale-Bohannon (MAS-B) Score of Optional Muscles Using a 6-Point Scale","description":"The MAS-B is a 6-point scale used to evaluate spasticity based on grading the resistance encountered in the optional muscles by passively moving the muscles through their range of motion. Optional muscles treated include: Rectus Femoris, Flexor Digitorum Longus, Flexor Hallucis Longus, and Extensor Hallucis. The scores range from 0 (no increase in muscle tone) to 4 (affected part(s) rigid in flexion or extension). Scores are converted to a 0 to 5 grade. A negative number change from baseline indicates an improvement and a positive number change from baseline indicates a worsening.","timeFrame":"Baseline, Week 6"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Diagnosis of post-stroke lower limb spasticity for at least 3 months\n* Minimum body weight of 50 kg\n* Never treated with botulinum toxin of any serotype for any reason, or if previously treated with botulinum toxin of any serotype, if previously treated for spasticity in the affected lower limb, must have been administered\n\n  * 20 weeks before Day 1, or if previously treated for any other indication must have been administered ≥12 weeks prior to Day 1\n\nExclusion Criteria:\n\n* Spasticity in the opposite leg that requires treatment\n* Casting of the study limb within 6 months or planned casting during the first 12 weeks of the study\n* Treatment modalities in the study limb including ultrasound, electrical nerve stimulation, electrical stimulation, acupuncture within 1 month of Day 1 or treatments planned during the study\n* Not able to perform 10 meter walking test independently with or without assistive device\n* Diagnosis of myasthenia gravis, Eaton-Lambert syndrome, or amyotrophic lateral sclerosis","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"85 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Medical Director","affiliation":"Allergan","role":"STUDY_DIRECTOR"}],"locations":[{"city":"Downey","state":"California","country":"United States","geoPoint":{"lat":33.94001,"lon":-118.13257}},{"city":"Daytona Beach","state":"Florida","country":"United States","geoPoint":{"lat":29.21081,"lon":-81.02283}},{"city":"Montreal","state":"Quebec","country":"Canada","geoPoint":{"lat":45.50884,"lon":-73.58781}},{"city":"Prague","country":"Czech Republic","geoPoint":{"lat":50.08804,"lon":14.42076}},{"city":"Wiesbaden","country":"Germany","geoPoint":{"lat":50.08258,"lon":8.24932}},{"city":"Würzburg","country":"Germany","geoPoint":{"lat":49.79391,"lon":9.95121}},{"city":"Budapest","country":"Hungary","geoPoint":{"lat":47.49801,"lon":19.03991}},{"city":"Gyeonggi-Do","country":"Korea, Republic of","geoPoint":{"lat":37.58944,"lon":126.76917}},{"city":"Krakow","country":"Poland","geoPoint":{"lat":50.06143,"lon":19.93658}},{"city":"Krasnoyarsk","country":"Russian Federation","geoPoint":{"lat":56.01839,"lon":92.86717}},{"city":"Stoke-on-Trent","state":"England","country":"United Kingdom","geoPoint":{"lat":53.00415,"lon":-2.18538}},{"city":"Fazakerley","state":"Liverpool","country":"United Kingdom","geoPoint":{"lat":53.4614,"lon":-2.92863}}]},"referencesModule":{"references":[{"pmid":"29330071","type":"DERIVED","citation":"Wein T, Esquenazi A, Jost WH, Ward AB, Pan G, Dimitrova R. OnabotulinumtoxinA for the Treatment of Poststroke Distal Lower Limb Spasticity: A Randomized Trial. PM R. 2018 Jul;10(7):693-703. doi: 10.1016/j.pmrj.2017.12.006. Epub 2018 Jan 9."}]}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"Botulinum Toxin Type A","description":"Double-Blind Study Phase (12 weeks): On Day 1, botulinum toxin Type A 300 U will be given by intramuscular injections into specified muscles of the lower limb, and an optional dose of 100 U may be injected into additional lower limb muscles. Open Label Study Phase: Up to 3 treatments with botulinum toxin Type A up to 400 U will be given by intramuscular injections to the lower limb approximately every 12 weeks over a 42 week period."},{"id":"FG001","title":"Normal Saline (Placebo) Followed by Botulinum Toxin Type A","description":"Double-Blind Study Phase (12 weeks): On Day 1, normal saline (placebo) will be given by intramuscular injections into specified muscles of the lower limb, and optional injections may be administered into additional lower limb muscles. Open Label Study Phase: Up to 3 treatments with botulinum toxin Type A up to 400 U will be given by intramuscular injections to the lower limb approximately every 12 weeks over a 42 week period."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"233"},{"groupId":"FG001","numSubjects":"235"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"204"},{"groupId":"FG001","numSubjects":"209"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"29"},{"groupId":"FG001","numSubjects":"26"}]}],"dropWithdraws":[{"type":"Other Reasons","reasons":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"3"}]},{"type":"Protocol Violation","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"1"}]},{"type":"Personal Reasons","reasons":[{"groupId":"FG000","numSubjects":"10"},{"groupId":"FG001","numSubjects":"11"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"3"}]},{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"9"},{"groupId":"FG001","numSubjects":"8"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Botulinum Toxin Type A","description":"Double-Blind Study Phase (12 weeks): On Day 1, botulinum toxin Type A 300 U will be given by intramuscular injections into specified muscles of the lower limb, and an optional dose of 100 U may be injected into additional lower limb muscles. Open Label Study Phase: Up to 3 treatments with botulinum toxin Type A up to 400 U will be given by intramuscular injections to the lower limb approximately every 12 weeks over a 42 week period."},{"id":"BG001","title":"Normal Saline (Placebo) Followed by Botulinum Toxin Type A","description":"Double-Blind Study Phase (12 weeks): On Day 1, normal saline (placebo) will be given by intramuscular injections into specified muscles of the lower limb, and optional injections may be administered into additional lower limb muscles. Open Label Study Phase: Up to 3 treatments with botulinum toxin Type A up to 400 U will be given by intramuscular injections to the lower limb approximately every 12 weeks over a 42 week period."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"233"},{"groupId":"BG001","value":"235"},{"groupId":"BG002","value":"468"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"Years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"56.0","spread":"12.60"},{"groupId":"BG001","value":"57.0","spread":"11.88"},{"groupId":"BG002","value":"56.5","spread":"12.24"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"85"},{"groupId":"BG001","value":"80"},{"groupId":"BG002","value":"165"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"148"},{"groupId":"BG001","value":"155"},{"groupId":"BG002","value":"303"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Modified Ashworth Scale-Bohannon (MAS-B) Score of Ankle Plantar Flexors Using a 6-Point Scale","description":"The MAS-B is a 6-point scale used to evaluate spasticity based on grading the resistance encountered in the ankle flexors by passively moving the ankle plantar flexor muscles through their range of motion. The score ranges from 0 (no increase in muscle tone) to 4 (affected part(s) rigid in flexion or extension). Scores are converted to a 0 to 5 grade. The average of the weeks 4 and 6 MAS-B ankle change from baseline is the primary end point. A negative number change from baseline indicates an improvement and a positive number change from baseline indicates a worsening.","populationDescription":"Intent-to-Treat: all randomized patients who were analyzed according to randomization assignment, regardless of treatment actually received","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Scores on a Scale","timeFrame":"Baseline, 6 Weeks","groups":[{"id":"OG000","title":"Botulinum Toxin Type A","description":"Double-Blind Study Phase (12 weeks): On Day 1, botulinum toxin Type A 300 U will be given by intramuscular injections into specified muscles of the lower limb, and an optional dose of 100 U may be injected into additional lower limb muscles. Open Label Study Phase: Up to 3 treatments with botulinum toxin Type A up to 400 U will be given by intramuscular injections to the lower limb approximately every 12 weeks over a 42 week period."},{"id":"OG001","title":"Normal Saline (Placebo) Followed by Botulinum Toxin Type A","description":"Double-Blind Study Phase (12 weeks): On Day 1, normal saline (placebo) will be given by intramuscular injections into specified muscles of the lower limb, and optional injections may be administered into additional lower limb muscles. Open Label Study Phase: Up to 3 treatments with botulinum toxin Type A up to 400 U will be given by intramuscular injections to the lower limb approximately every 12 weeks over a 42 week period."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"233"},{"groupId":"OG001","value":"235"}]}],"classes":[{"title":"Baseline","categories":[{"measurements":[{"groupId":"OG000","value":"4.1","spread":"0.27"},{"groupId":"OG001","value":"4.1","spread":"0.25"}]}]},{"title":"Change from Baseline at 6 weeks","categories":[{"measurements":[{"groupId":"OG000","value":"-0.81","spread":"0.874"},{"groupId":"OG001","value":"-0.61","spread":"0.835"}]}]}]},{"type":"SECONDARY","title":"Clinical Global Impression (CGI) of Overall Change by Physician Using a 9-Point Scale","description":"The CGI is a 9-point scale evaluating change from baseline status by the Physician. Scores range from +4 (very marked improvement) to -4 (very marked worsening). The average of the weeks 4 and 6 CGI by Physician score is used as a secondary end point. Higher scores indicate a greater improvement from baseline.","populationDescription":"Intent-to-Treat: all randomized patients who were analyzed according to randomization assignment, regardless of treatment actually received","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Scores on a Scale","timeFrame":"Baseline, 6 weeks","groups":[{"id":"OG000","title":"Botulinum Toxin Type A","description":"Double-Blind Study Phase (12 weeks): On Day 1, botulinum toxin Type A 300 U will be given by intramuscular injections into specified muscles of the lower limb, and an optional dose of 100 U may be injected into additional lower limb muscles. Open Label Study Phase: Up to 3 treatments with botulinum toxin Type A up to 400 U will be given by intramuscular injections to the lower limb approximately every 12 weeks over a 42 week period."},{"id":"OG001","title":"Normal Saline (Placebo) Followed by Botulinum Toxin Type A","description":"Double-Blind Study Phase (12 weeks): On Day 1, normal saline (placebo) will be given by intramuscular injections into specified muscles of the lower limb, and optional injections may be administered into additional lower limb muscles. Open Label Study Phase: Up to 3 treatments with botulinum toxin Type A up to 400 U will be given by intramuscular injections to the lower limb approximately every 12 weeks over a 42 week period."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"233"},{"groupId":"OG001","value":"235"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.86","spread":"0.953"},{"groupId":"OG001","value":"0.65","spread":"0.902"}]}]}]},{"type":"SECONDARY","title":"Goal Attainment Scores on the 6-Point Physician-Assessed Goal Attainment Scale (GAS)","description":"The physician-assessed GAS is an individualized, goal-oriented 6-point scale used to track functional improvement toward active and passive goals. GAS scoring ranged from -3 to 2 (-3 = worse than start; 0 = expected goal/attained the defined therapeutic goal; 2 = much more than expected/improvements clearly exceeded the defined therapeutic goal). Active and Passive Goal scores are presented.","populationDescription":"Intent-to-Treat: all randomized patients who were analyzed according to randomization assignment, regardless of treatment actually received","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Scores on a Scale","timeFrame":"Week 8","groups":[{"id":"OG000","title":"Botulinum Toxin Type A","description":"Double-Blind Study Phase (12 weeks): On Day 1, botulinum toxin Type A 300 U will be given by intramuscular injections into specified muscles of the lower limb, and an optional dose of 100 U may be injected into additional lower limb muscles. Open Label Study Phase: Up to 3 treatments with botulinum toxin Type A up to 400 U will be given by intramuscular injections to the lower limb approximately every 12 weeks over a 42 week period."},{"id":"OG001","title":"Normal Saline (Placebo) Followed by Botulinum Toxin Type A","description":"Double-Blind Study Phase (12 weeks): On Day 1, normal saline (placebo) will be given by intramuscular injections into specified muscles of the lower limb, and optional injections may be administered into additional lower limb muscles. Open Label Study Phase: Up to 3 treatments with botulinum toxin Type A up to 400 U will be given by intramuscular injections to the lower limb approximately every 12 weeks over a 42 week period."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"233"},{"groupId":"OG001","value":"235"}]}],"classes":[{"title":"Active Goals (N=226, 228)","categories":[{"measurements":[{"groupId":"OG000","value":"-0.8","spread":"1.34","lowerLimit":"-0.99","upperLimit":"-0.56"},{"groupId":"OG001","value":"-1.0","spread":"1.33","lowerLimit":"-1.19","upperLimit":"-0.76"}]}]},{"title":"Passive Goals--use (N=214, 217)","categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":"1.42","lowerLimit":"-0.77","upperLimit":"-0.31"},{"groupId":"OG001","value":"-0.8","spread":"1.33","lowerLimit":"-1.01","upperLimit":"-0.57"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Average Pain Score While Walking on the 11-Point Pain Scale","description":"The patient is asked to select a number that best describes his/her pain while walking on an 11-point scale from 0 = \"no pain\" to 10 = \"pain as bad as can be imagined\". Patients are instructed to recall their average pain in the study limb during the 48-hour period prior to the visit. Patients with a baseline pain score \\>0 are included in the analyses.","populationDescription":"Intent-to-Treat: all randomized patients who were analyzed according to randomization assignment, regardless of treatment actually received","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Scores on a Scale","timeFrame":"Baseline, Week 6","groups":[{"id":"OG000","title":"Botulinum Toxin Type A","description":"Double-Blind Study Phase (12 weeks): On Day 1, botulinum toxin Type A 300 U will be given by intramuscular injections into specified muscles of the lower limb, and an optional dose of 100 U may be injected into additional lower limb muscles. Open Label Study Phase: Up to 3 treatments with botulinum toxin Type A up to 400 U will be given by intramuscular injections to the lower limb approximately every 12 weeks over a 42 week period."},{"id":"OG001","title":"Normal Saline (Placebo) Followed by Botulinum Toxin Type A","description":"Double-Blind Study Phase (12 weeks): On Day 1, normal saline (placebo) will be given by intramuscular injections into specified muscles of the lower limb, and optional injections may be administered into additional lower limb muscles. Open Label Study Phase: Up to 3 treatments with botulinum toxin Type A up to 400 U will be given by intramuscular injections to the lower limb approximately every 12 weeks over a 42 week period."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"180"},{"groupId":"OG001","value":"164"}]}],"classes":[{"title":"Baseline","categories":[{"measurements":[{"groupId":"OG000","value":"4.5","spread":"1.95"},{"groupId":"OG001","value":"4.5","spread":"2.13"}]}]},{"title":"Change from Baseline at Week 6 (N=175, 158)","categories":[{"measurements":[{"groupId":"OG000","value":"-0.8","spread":"2.30"},{"groupId":"OG001","value":"-1.1","spread":"2.38"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Modified Ashworth Scale-Bohannon (MAS-B) Score of Optional Muscles Using a 6-Point Scale","description":"The MAS-B is a 6-point scale used to evaluate spasticity based on grading the resistance encountered in the optional muscles by passively moving the muscles through their range of motion. Optional muscles treated include: Rectus Femoris, Flexor Digitorum Longus, Flexor Hallucis Longus, and Extensor Hallucis. The scores range from 0 (no increase in muscle tone) to 4 (affected part(s) rigid in flexion or extension). Scores are converted to a 0 to 5 grade. A negative number change from baseline indicates an improvement and a positive number change from baseline indicates a worsening.","populationDescription":"Intent-to-Treat: all randomized patients who were analyzed according to randomization assignment, regardless of treatment actually received","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Scores on a Scale","timeFrame":"Baseline, Week 6","groups":[{"id":"OG000","title":"Botulinum Toxin Type A","description":"Double-Blind Study Phase (12 weeks): On Day 1, botulinum toxin Type A 300 U will be given by intramuscular injections into specified muscles of the lower limb, and an optional dose of 100 U may be injected into additional lower limb muscles. Open Label Study Phase: Up to 3 treatments with botulinum toxin Type A up to 400 U will be given by intramuscular injections to the lower limb approximately every 12 weeks over a 42 week period."},{"id":"OG001","title":"Normal Saline (Placebo) Followed by Botulinum Toxin Type A","description":"Double-Blind Study Phase (12 weeks): On Day 1, normal saline (placebo) will be given by intramuscular injections into specified muscles of the lower limb, and optional injections may be administered into additional lower limb muscles. Open Label Study Phase: Up to 3 treatments with botulinum toxin Type A up to 400 U will be given by intramuscular injections to the lower limb approximately every 12 weeks over a 42 week period."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"143"},{"groupId":"OG001","value":"133"}]}],"classes":[{"title":"Baseline Rectus Femoris (N=25, 25)","categories":[{"measurements":[{"groupId":"OG000","value":"3.3","spread":"0.58"},{"groupId":"OG001","value":"3.2","spread":"0.59"}]}]},{"title":"Chng from BL at Wk6 in Rectus Femoris (N=24,25)","categories":[{"measurements":[{"groupId":"OG000","value":"-0.9","spread":"0.87"},{"groupId":"OG001","value":"-1.0","spread":"1.14"}]}]},{"title":"Baseline Flexor Digitorum Longus (N=86,88)","categories":[{"measurements":[{"groupId":"OG000","value":"3.3","spread":"0.76"},{"groupId":"OG001","value":"3.4","spread":"0.70"}]}]},{"title":"Chng from BL at Wk6 in Digitorum Longus (N=85,84)","categories":[{"measurements":[{"groupId":"OG000","value":"-0.9","spread":"1.11"},{"groupId":"OG001","value":"-0.8","spread":"1.22"}]}]},{"title":"Baseline Flexor Hallucis Longus (N=73,67)","categories":[{"measurements":[{"groupId":"OG000","value":"3.1","spread":"0.81"},{"groupId":"OG001","value":"3.2","spread":"0.83"}]}]},{"title":"Chng frm BL at Wk6 Flexor Hallucis Longus(N=72,66)","categories":[{"measurements":[{"groupId":"OG000","value":"-1.0","spread":"1.30"},{"groupId":"OG001","value":"-0.6","spread":"1.20"}]}]},{"title":"Baseline Extensor Hallucis (N=23,13)","categories":[{"measurements":[{"groupId":"OG000","value":"3.6","spread":"0.49"},{"groupId":"OG001","value":"3.6","spread":"0.51"}]}]},{"title":"Chng from BL at Wk6 in Extensor Hallucis (N=23,13)","categories":[{"measurements":[{"groupId":"OG000","value":"-1.3","spread":"1.22"},{"groupId":"OG001","value":"-1.3","spread":"1.09"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","description":"The safety population during the 12-week double-blind phase included all enrolled patients who received at least 1 treatment injection in the study. The double-blind safety population is used to assess adverse events and serious adverse events.","eventGroups":[{"id":"EG000","title":"Botulinum Toxin Type A","description":"Double-Blind Study Phase (12 weeks): On Day 1, botulinum toxin Type A 300 U will be given by intramuscular injections into specified muscles of the lower limb, and an optional dose of 100 U may be injected into additional lower limb muscles.","seriousNumAffected":10,"seriousNumAtRisk":231,"otherNumAffected":0,"otherNumAtRisk":231},{"id":"EG001","title":"Normal Saline (Placebo)","description":"Double-Blind Study Phase (12 weeks): On Day 1, normal saline (placebo) will be given by intramuscular injections into specified muscles of the lower limb, and optional injections may be administered into additional lower limb muscles.","seriousNumAffected":9,"seriousNumAtRisk":233,"otherNumAffected":0,"otherNumAtRisk":233}],"seriousEvents":[{"term":"Bifascicular block","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA version 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":231},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Bradycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA version 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":231},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Bundle branch block left","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA version 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":231},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Bundle branch block right","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA version 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":231},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Coronary artery disease","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA version 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":231},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Mitral valve incompetence","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA version 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":231},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Gastric ulcer","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":231},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Cholecystitis chronic","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA version 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":231},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Chronic sinusitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":231},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Pilonidal cyst","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":231},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":231},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Concussion","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA version 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":231},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Vascular pseudoaneurysm","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA version 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":231},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA version 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":231},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA version 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":231},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Barbiturates positive","organSystem":"Investigations","sourceVocabulary":"MedDRA version 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":231},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Opiates positive","organSystem":"Investigations","sourceVocabulary":"MedDRA version 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":231},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA version 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":231},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Hepatic cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA version 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":231},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Cerebrovascular accident","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA version 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":231},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Ischaemic stroke","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA version 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":231},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Depression","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA version 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":231},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Drug abuse","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA version 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":231},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Schizoaffective disorder","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA version 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":231},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Bullous lung disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":231},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Mediastinal haemorrhage","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":231},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Blister","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA version 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":231},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA version 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":231},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Peripheral ischaemia","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA version 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":231},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Musculoskeletal chest pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA version 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":231},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo."},"pointOfContact":{"title":"Therapeutic Area Head,","organization":"Allergan, Inc","email":"clinicaltrials@allergan.com","phone":"714-246-4500"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000009128","term":"Muscle Spasticity"}],"ancestors":[{"id":"D000009135","term":"Muscular Diseases"},{"id":"D000009140","term":"Musculoskeletal Diseases"},{"id":"D000009122","term":"Muscle Hypertonia"},{"id":"D000020879","term":"Neuromuscular Manifestations"},{"id":"D000009461","term":"Neurologic Manifestations"},{"id":"D000009422","term":"Nervous System Diseases"}],"browseLeaves":[{"id":"M21996","name":"Stroke","relevance":"LOW"},{"id":"M11775","name":"Muscle Spasticity","asFound":"Muscle Spasticity","relevance":"HIGH"},{"id":"M11782","name":"Muscular Diseases","relevance":"LOW"},{"id":"M11787","name":"Musculoskeletal Diseases","relevance":"LOW"},{"id":"M11769","name":"Muscle Hypertonia","relevance":"LOW"},{"id":"M22309","name":"Neuromuscular Manifestations","relevance":"LOW"},{"id":"M12094","name":"Neurologic Manifestations","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC05","name":"Musculoskeletal Diseases"},{"abbrev":"BC23","name":"Symptoms and General Pathology"}]},"interventionBrowseModule":{"meshes":[{"id":"D000001905","term":"Botulinum Toxins"},{"id":"D000019274","term":"Botulinum Toxins, Type A"},{"id":"C000542869","term":"abobotulinumtoxinA"}],"ancestors":[{"id":"D000065087","term":"Acetylcholine Release Inhibitors"},{"id":"D000049990","term":"Membrane Transport Modulators"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D000018678","term":"Cholinergic Agents"},{"id":"D000018377","term":"Neurotransmitter Agents"},{"id":"D000045505","term":"Physiological Effects of Drugs"},{"id":"D000009465","term":"Neuromuscular Agents"},{"id":"D000018373","term":"Peripheral Nervous System Agents"}],"browseLeaves":[{"id":"M4873","name":"Botulinum Toxins","asFound":"250","relevance":"HIGH"},{"id":"M250157","name":"abobotulinumtoxinA","asFound":"Previous","relevance":"HIGH"},{"id":"M20947","name":"Botulinum Toxins, Type A","asFound":"Previous","relevance":"HIGH"},{"id":"M83865","name":"Trichostatin A","relevance":"LOW"},{"id":"M3163","name":"Acetylcholine","relevance":"LOW"},{"id":"M20448","name":"Cholinergic Agents","relevance":"LOW"},{"id":"M20194","name":"Neurotransmitter Agents","relevance":"LOW"}],"browseBranches":[{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"Infe","name":"Anti-Infective Agents"},{"abbrev":"VaDiAg","name":"Vasodilator Agents"}]}},"hasResults":true}